Combination immune therapy and cytokine control therapy for cancer treatment
Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions including apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do not reduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm including administration of a composition including apoptotic cells or an apoptotic cell supernatant.
1. A method of inhibiting or reducing the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject undergoing chimeric antigen receptor-expressing T-cell (CAR T-cell) cancer therapy, the method comprising the step of administering a composition to said subject, the composition comprising (a) chimeric antigen receptor-expressing T-cells (CAR T-cells) and a pharmaceutically acceptable excipient, and (b) either early apoptotic cells or an early apoptotic cell supernatant, and a pharmaceutically acceptable excipient, wherein said early apoptotic cells are ≥40% AnnexinV + and ≤15% propidium iodide + , and wherein said early apoptotic cells are peripheral blood mononuclear cells.
2. The method of claim 1 , wherein said early apoptotic cells are autologous to the subject or are pooled third-party donor cells.
3. The method of claim 1 , wherein said method further comprises administering an additional agent selected from the group comprising a CTLA-4 blocking agent, a tellurium-based compound, an alpha-1 anti-trypsin or fragment thereof or analogue thereof, or an immune modulating agent, or any combination thereof.
4. The method of claim 3 , wherein administration of said additional agent occurs prior to the CAR T-cell therapy.
5. The method of claim 3 , wherein administration of said additional agent occurs concurrent with the CAR T-cell therapy.
6. The method of claim 3 , wherein administration of said additional agent occurs following the CAR T-cell therapy.